Open Trials - Recruiting - TROG Cancer Research

TROG 21.12 – ASPIRE

Australian Particle Therapy Clinical Quality Registry

TROG 18.01 – NINJA

Novel Integration of New prostate radiation therapy schedules with adJuvant Androgen deprivation

TROG 18.06 – FIG

Prospective, multicentre trial evaluating FET-PET in Glioblastoma

TROG 19.06 – DECREASE

DarolutamidE + Consolidation Radiotherapy in Advanced prostate cancer detected by PSMA

TROG 20.01 – CHEST RT

Chemotherapy Immunotherapy in Extensive Stage Small Cell with Thoracic Radiation therapy

TROG 21.07 – SOCRATES HCC

A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC

AGITG/TROG 21.03 – RESOLUTE

Randomised Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

AGITG/TROG 18.04 – MASTERPLAN

A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease

ANZ 1601/BIG 16-02/TROG 16.04 – EXPERT

Examining Personalised Radiation Therapy for Low-risk Early Breast Cancer

ANZGOG/TROG 21.04 – ADELE

ADjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk EndometriaL cancer (ADELE): a randomised phase 2 trial

ANZUP 1801/TROG 21.02 DASL-HiCaP

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

MASC 03.18/TROG 21.01 – I-MAT

A randomised, placebo-controlled, Phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma

R2810-ONC-1788/TROG 17.11 – CPOST

A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma

E33036 IAEA HCC

RANDOMIZED STUDY OF STEREOTACTIC BODY RADIATION THERAPY (SBRT) VERSUS TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN HEPATOCELLUAR CARCINOMA

E33039 IAEA NPC

A Situation Analysis of National Radiotherapy Resources and Patterns of Care for Patients with Nasopharyngeal Carcinoma in Low-Middle Income Countries: Can Enhancing the Quality of Radiotherapy Planning Improve Outcomes

SEAFARER

RTQA: Sensitivity Assessment System to Improve Quality in Radiation Oncology Treatment (SEAFARER)

VESPA

RTQA: Virtual EPID Standard Phantom Audit

Open Trials – Recruiting